Akeso (HKSE:09926) Days Payable : 1,017.41 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Akeso Days Payable?

Akeso's average Accounts Payable for the six months ended in Dec. 2023 was HK$342 Mil. Akeso's Cost of Goods Sold for the six months ended in Dec. 2023 was HK$61 Mil. Hence, Akeso's Days Payable for the six months ended in Dec. 2023 was 1,017.41.

The historical rank and industry rank for Akeso's Days Payable or its related term are showing as below:

HKSE:09926' s Days Payable Range Over the Past 10 Years
Min: 858.82 Med: 1037.73 Max: 1840.99
Current: 858.82

During the past 6 years, Akeso's highest Days Payable was 1840.99. The lowest was 858.82. And the median was 1037.73.

HKSE:09926's Days Payable is ranked better than
83.17% of 719 companies
in the Biotechnology industry
Industry Median: 147.29 vs HKSE:09926: 858.82

Akeso's Days Payable increased from Dec. 2022 (830.97) to Dec. 2023 (1,017.41). It may suggest that Akeso delayed paying its suppliers.

Akeso Days Payable Historical Data

The historical data trend for Akeso's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso Days Payable Chart

Akeso Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

1,840.99

1,037.73

918.00

Akeso Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Payable	Get a 7-Day Free Trial						908.09	1,603.14	830.97	692.52	1,017.41

Competitive Comparison of Akeso's Days Payable

For the Biotechnology subindustry, Akeso's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akeso's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akeso's Days Payable distribution charts can be found below:

* The bar in red indicates where Akeso's Days Payable falls into.

Akeso Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Akeso's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (345.007	+	388.103)	/	2 )	/	145.744	*	365
=	366.555					/	145.744	*	365
=	918.00

Akeso's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (295.662	+	388.103)	/	2 )	/	61.326	*	365 / 2
=	341.8825					/	61.326	*	365 / 2
=	1,017.41

Akeso Days Payable Related Terms

Thank you for viewing the detailed overview of Akeso's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Akeso (HKSE:09926) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

AKESF:USA 4RY:Germany

Address

6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437

Website

https://www.akesobio.com

Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.

Akeso (HKSE:09926) Headlines

No Headlines